Impact Biomedical (IBO) Free Cash Flow (2022 - 2026)
Impact Biomedical (IBO) posted Free Cash Flow of -$464000.0 for Q1 2026, down 568.69% on a QoQ basis from $99000.0 in Q4 2025, and up 31.96% year-over-year from -$351608.9 in Q1 2025.
Impact Biomedical (IBO) Free Cash Flow (2022 - 2026) Analysis & Trends
Impact Biomedical's Free Cash Flow history runs 5 years deep, the most recent figure standing at -$464000.0 for Q1 2026.
- Quarterly Free Cash Flow rose 31.96% year-over-year to -$464000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.7 million (up 45.25% YoY) and the FY2025 annual result came in at -$1.9 million, up 33.78% from the prior year.
- Free Cash Flow was -$464000.0 for Q1 2026 at Impact Biomedical, down from $99000.0 in the prior quarter.
- Across five years, Free Cash Flow topped out at $99000.0 in Q4 2025 and bottomed at -$1.0 million in Q1 2023.
- A 5-year average of -$616133.3 and a median of -$672000.0 in 2023 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2024 — Free Cash Flow tumbled 127.71% — and 2025, when it soared 110.04%.
- Impact Biomedical's Free Cash Flow stood at -$363000.0 in 2022, then retreated by 19.28% to -$433000.0 in 2023, then tumbled by 127.71% to -$986000.0 in 2024, then surged by 110.04% to $99000.0 in 2025, then sank by 568.69% to -$464000.0 in 2026.
- Business Quant data shows IBO's Free Cash Flow at -$464000.0 in Q1 2026, $99000.0 in Q4 2025, and -$613000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Impact Biomedical | 47.44 Mn | 50.67 Mn | - | -464,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -464,000.00 |
| Mar 31, 2026 | -464,000.00 |
| Dec 31, 2025 | 99,000.00 |
| Dec 31, 2025 | 99,000.00 |
| Sep 30, 2025 | -613,000.00 |
| Sep 30, 2025 | -613,000.00 |
| Jun 30, 2025 | -694,000.00 |
| Jun 30, 2025 | -694,000.00 |
| Mar 31, 2025 | -682,000.00 |
| Mar 31, 2025 | -682,000.00 |
| Dec 31, 2024 | -986,000.00 |
| Dec 31, 2024 | -986,000.00 |
| Sep 30, 2024 | -1.00 Mn |
| Sep 30, 2024 | -1.00 Mn |
| Jun 30, 2024 | -385,000.00 |
| Jun 30, 2024 | -385,000.00 |
| Mar 31, 2024 | -482,000.00 |
| Mar 31, 2024 | -482,000.00 |
| Dec 31, 2023 | -433,000.00 |
| Dec 31, 2023 | -433,000.00 |